Gubra Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Hoersholm, Denmark
Total Funding:N/A
Industry:Biotech
Founded:2008
Lead Investor(s):N/A

Industry Ranking

Estimated Revenue & Financials

  • Gubra's estimated annual revenue is currently $27.7M per year.
  • Gubra's estimated revenue per employee is $155,000

Employee Data

  • Gubra has 179 Employees.
  • Gubra grew their employee count by 34% last year.
  • Gubra currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingPricing
Genmab
$98.4M63537%N/AN/A
Gubra
$27.7M17934%N/AN/A
Unibio
$8.4M548%N/AN/A
Orphazyme
$24.8M16045%N/AN/A
Ascendis Pharma...
$63.1M40745%N/AN/A
Missing a competitor? Contribute!?
Submit

Founded in 2008, we are a privately-held biotech company with two primary areas of business: Pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs. Our focus is the metabolic space (obesity, diabetes, NASH and gastrointestinal diseases), where we specialize in in vivo pharmacology, peptide chemistry, molecular pharmacology, histology, imaging, stereology, NGS (next generation sequencing), bioinformatics and ex vivo assays. Gubra is an abbreviation for GUt and BRAin, the original key focus areas of our research and expertise. We work with some of the most interesting and loyal partners and customer from across the world within big pharma, biotech and academia. Through a constant focus on high quality, scientific excellence, speed and solid teamwork, we have established ourselves as a highly professional and competent partner in the market.

keywords:N/A

179

Number of Employees

$27.7M

Revenue (est)

1

Current Jobs

34%

Employee Growth %

N/A

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Gubra News

05/30/2019 - Boehringer adds to obesity alliance with Denmark's Gubra

Two years after they started working together, Boehringer Ingelheim and Gubra have taken their obesity collaboration to a higher level.

05/29/2019 - Gubra to get up to 240 million euros in new Boehringer deal

German pharma major Boehringer Ingelheim and Danish biotech Gubra have announced a second collaboration and license agreement for ...

05/29/2019 - Boehringer Ingelheim and Gubra announce new collaboration ...

INGELHEIM, Germany & H├śRSHOLM, Denmark--(BUSINESS WIRE)--Boehringer Ingelheim and Gubra announce a second collaboration and ...